Mercaptopurin-Medice

Mercaptopurine, the active ingredient in Mercaptopurin-Medice, is a thiopurine presented as an oral tablet for oral use. It is employed in the treatment of certain leukemias and inflammatory bowel diseases, targeting rapidly dividing cells. GNH USA supplies Mercaptopurin-Medice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mercaptopurin-Medice is a thiopurine used in hematologic malignancies and inflammatory bowel disorders. - Acute lymphoblastic leukemia (ALL): helps achieve remission and maintain disease control. - Chronic myeloid leukemia (CML): used in combination regimens to obtain cytogenetic and molecular responses. - Inflammatory bowel disease (Crohn's disease, ulcerative colitis): contributes to disease remission and reduces intestinal inflammation.

Mercaptopurin-Medice may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting - Loss of appetite - Mild infections (e.g., upper respiratory) - Elevated liver enzymes - Hair thinning or loss - Fatigue

Serious or Rare Side Effects: - Severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) - Pancreatitis - Hepatotoxicity with jaundice - Life‑threatening infections - Severe hypersensitivity reactions (rash, fever, organ involvement) - Development of secondary malignancies such as myelodysplastic syndrome.

Before initiating therapy, clinicians should assess baseline parameters and monitor patients closely. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess liver function: check transaminases and bilirubin periodically. - Adjust dose in renal impairment: reduce dosage based on creatinine clearance. - Avoid use in known hypersensitivity: discontinue if allergic reaction occurs. - Counsel on infection risk: advise patients to report fever or signs of infection promptly. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mercaptopurin-Medice can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Allopurinol: may increase mercaptopurine toxicity and cause severe myelosuppression. - Azathioprine: additive bone‑marrow suppression when used together. - Warfarin: can potentiate anticoagulant effect, raising INR.

Moderate Interactions (Monitor Closely): - 5‑ASA agents (e.g., mesalamine): may alter mercaptopurine metabolism. - NSAIDs: increase risk of gastrointestinal irritation and bleeding.